Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
jefferies $Qure QURE notes unfavorable preliminary EU regulatory opinion for Glybera in LPLD on 6-yr FU data; similar to previous review prior to approval under exceptional circumstances in 10/12. CHMP decision is expected in ~2-3 months. With much slower-than-guided EU launch timeline, expectations for Glybera have been low and such negative regulatory review, while not new, does not help. We now assume 50% probability-adjusted EU Glybera potential. On 6-year follow-up data, CAT-designated rapporteur reports lack of efficacy and negative benefit risk balance for Glybera in LPLD; QURE said not surprised given the similar position taken previously. Based on final clinical study report including the six-year follow-up data, the assessment report states that the rapporteur considers that Glybera lacks efficacy and therefore that the benefit-risk balance of Glybera is negative. Glybera was approved under exceptional circumstances in EU on 10/31/12. QURE notes that with approval under exceptional circumstances, review of efficacy/safety upon additional data availability is a normal process. QURE expects resolution in next ~2-3 months; still likely that EMA could await Ph4 results (study to begin early-2016) before potential reversal of marketing authorization per QURE. This report will be reviewed at upcoming CAT (4/16-4/17/15) and CHMP meetings (4/21-4/23/15). Though not ruling out possibility for EU marketing authorization removal, QURE notes that it is still very likely that EU regulatory bodies wait to see Ph4 results for Glybera (initiation expected in early-2016) before reversing its position. Glybera accounts for <10% of our QURE valuation; its EU launch has been very slow & partner Chiesi is yet to generate sales revenue (vs. EU launch in ~1H14 originally). Even with continued EU marketing authorization, it is highly likely that sales would be very slow; our current cumulative sales of ~$480M could be aggressive. Resetting PT to $40 (from $42) on decreased EU Glybera probability of success to 50% (from 100% prior). Our $40 PT now includes $3/sh for Glybera (vs. $5/sh previously).twitter.com/biorunup
Super Flosz! Iedereen lees bovenstaande tweet aandachtig als je een afgewogen risicoanalyse wil hebben over Glybera, en maak op grond daarvan een belsuit over hoe je denkt dat het verder gaat. Veel beter info krijg je niet. Ik denk dat iemand van Jefferies met Reg Affairs bij QURE heeft gesproken en dat dit de gebalanceerde weergave is van het gesprek. Grootste kans is dat Glybera niet wordt teruggetrokken en dat de koers daarna weer als een dolle opveert. Kleinste kans is het omgekeerde en dan gaat de koers flink onderuit totdat de markt zich bewust wordt dat de waarde van QURE elders zit. In dat geval kan je bijkopen op het dieptepunt. Ben je kotsmisselijk van deze achtbaan: pak nu je winst. NOGMAALS DEZE TWEET IS M.I. EEN HEEL
Na AMT kunnen we hier toch wel wat hebben....haha. Heb er vertrouwen in, alles sal reg kom, al was het alleen al vanwege de patiënten zoals Prof. Dollar op twitter reeds aan gaf.
Leerink $QURE ( $CLDN ) Risk/Reward Compelling Ahead of Potential Catalysts, in Our View • Bottom Line: On 4/9 QURE disclosed in a filing that it received an assessment report as part of its ongoing EU regulatory procedure to update the Glybera label to include additional six-year follow-up data. In the report the rapporteur concludes that the benefit-risk balance of Glybera is negative. Although surprising to us, the report reflects only a part in a complex regulatory process, the outcome of which depends on QURE's negotiation with regulators over the next 3-4 months. We note that Glybera is only a small value driver for the stock, given its limited commercial potential, and we believe with the recently announced BMY (OP) partnership, QURE is well positioned to capitalize on its gene therapy platform ahead of news flow including CLDN CUPID2 data in April, and QURE hemophilia B and Sanfilippo B Phase I data in 2H15. Reiterating Outperform rating. • QURE announced in a filing on 4/9 that it received an assessment report from EU regulators questioning the risk-benefit profile of Glybera. The report by the CAT (Committee for Advanced Therapy Medicinal Products) rapporteur is part of QURE's ongoing EU regulatory process to update the Glybera EU label to include additional six-year follow-up data. The report states the rapporteur considers that Glybera lacks efficacy and therefore that the benefit-risk balance of Glybera is negative. Recall QURE reported the six-year follow-up data last June and showed a 40-50% lower post-treatment pancreatitis rate. The CAT advises the EMA’s CHMP on gene therapies; however the views of the rapporteur are not binding. • The CAT report reflects the first step in a complex regulatory process over the next 3-4 months, involving repeated requests for additional information after a CHMP meeting. Mgmt expects to have additional requests after April 23rd and will then have an additional 30-60 days to respond. This will then initiate another 30-60 day review by the CAT/CHMP before reaching a conclusion. Based on mgmt comments, we believe the rapporteur opinion reflects an ongoing discussion about the robustness and meaningfulness of the clinical benefit of Glybera and the rapporteur has been critical since the beginning of the program. Regardless of the outcome of the process which could include the request for additional supportive clinical data, we note that Glybera is only a small value driver for the stock. We currently model 2015E, '16E, and '17E EU Glybera royalties of EUR 2, 3, and 8M. respectively, and Glybera EU royalties reflect only 10% of our $50 price target. • Potential positive read through from CLDN CUPID2 data this month. Whereas positive CUPID2 data could derisk the congestive heart failure (CHF) opportunity for gene therapy in general and hence BMY/QURE's program, we believe potentially disappointing CUPID2 data position QURE well to move forward with a strong partner and a potentially differentiated lead CHF asset. We believe BMY has recognized the opportunity in QURE's platform and has hence licensed QURE's CHF program before CLDN data have been publicly released. We note that QURE/BMY's lead CV program could also be differentiated from CLDN's in terms of: (1) cardiac delivery, (2) vector design, and (3) the gene payload. QURE has employed retrograde coronary venous delivery in animal models while CLDN is utilizing antegrade coronary artery infusion. Our checks with MEDACorp KOLs suggest that the retrograde approach could be more efficient given the ability to infuse vector at a greater pressure gradient, which would lead to greater transfer to the heart muscle tissue. While QURE has not yet committed to a specific AAV vector, it is utilizing a cardiomyocyte-specific promoter vs. CLDN's CMV promoter. One KOL we spoke with noted that the key rate limiter to high transduction efficiency is getting the virus delivered to the heart across the endothelial barrier. Hence, vector choice and dose are important factors influencing success chances. KOLs we spoke with were in agreement that both the SERCA2a gene (used by CLDN) and the S100A1 gene (used by QURE) hold significant promise. However, one KOL noted that S100A1 could be more potent than SERCA2a given its involvement in several aspects of the heart function. • Key value drivers in 2H15 include hemophilia B and Sanfilippo B data. We believe durable and consistent Factor IX expression in hemophilia B patients would be a key de-risking data point for QURE's liver-targeted pipeline. Positive Sanfilippo B data in 2H15 could validate the potential opportunity in CNS/lysosomal storage diseases (LSDs), representing another near-term source of upside, which is not yet accounted for in our valuation.mobile.twitter.com/captainfuture__
Piper: $QURE note 4/13 Last week, unfortunately timed with its secondary offering, QURE was notified by the CHMP that a negative assessment on Glybera is being submitted to the CAT (Committee for advanced Therapy Medicinal Products) which theoretically places the drug's EU approval at risk. The CHMP held the same negative view the first time Glybera was approved, so we are skeptical it will have any impact this time. Even if it does, QURE has become far less reliant on EU Glybera prospects as the hemophilia B gene therapy program has advanced to the clinic and it recently signed a transformative partnership with BMY. We reiterate our $40 PT. • More of the same? After review of the 6-year follow-up data for Glybera, the CHMP rapporteur has concluded the drug has not demonstrated robust efficacy and as such the benefit-risk balance is negative. This is the same conclusion the CHMP had prior to Glybera approval, which required 4 CAT committee meetings to assess. After an initial CAT negative vote, the subsequent ones were all positive because it was decided that the drug's effect on post-prandial chylomicrons was much more relevant for predicting pancreatitis risk than the drug's overall effect on triglycerides; a perspective we share. • What's next: The rapporteur's report will be submitted to the CAT for further assessment. The analysis is likely to be considered during an April 21-23 meeting; following this meeting there may be additional correspondence with the company to clarify any outstanding questions. A final decision may take up to a few months. We'd be surprised if the 6 year update led to any different decision by the CAT this time around. • Worst case: If the CAT reversed its prior views and decided to pull Glybera from the market, it would have a modest impact on our valuation (<25% impact) since we assume only modest contribution given a slow launch and royalty partially offset by payments owed. At this year's Phacilitate conference we had an opportunity to speak with one of the CHMP members who had been opposed to Glybera's approval- she was quite clear that this was not because it was a gene therapy product but because she didn't believe the drug had clear efficacy. She fully expected other gene therapy products will be approved on the basis of a larger demonstrated effect size. As such, we do not believe there should be any negative readthroughs even in the unlikely circumstance that Glybera is withdrawn. Ook via link vorige post.
Roth. We initiate coverage of uniQure N.V. (QURE) with a Buy rating and a $38/share price target.ROTH nice report on $QURE t.co/eOMauACLpn Glybera $1.50/share
Ratings Breakdown:5 Buy Rating(s) Consensus Rating:Buy (Score: 3.00) Consensus Price Target:$41.80 (43.99% upside)
BMO Capital Initiates Coverage on uniQure at Outperform, Announces $49.00 PT Afb. via:twitter.com/ymscapital
flosz schreef op 23 april 2015 00:35 :
BMO Capital Initiates Coverage on uniQure at Outperform, Announces $49.00 PT
Afb. via:
twitter.com/ymscapital misschien is dit de trigger voor de hogere koers in de after market? (weet niet wanneer het bericht verscheen?) Hemofilie A partnering zou overigens ook een top-bericht kunnen zijn.
Eerste berichtgeving tussen 23.00 en 24:00u.
Chardan Capital Markets Starts uniQure BV (QURE) at Buy with a price target of $40;Sees 2015 as 'Breakthrough' Year www.streetinsider.com/dr/news.php?id=...
finance.yahoo.com/news/hottest-niche-... The Hottest Niche in Biotech Still Has Ample Upside StreetAuthority Network 4 minutes ago Over the past half decade, large biotechnology stocks have delivered robust gains across the board. These companies sell a range of very popular drugs and have been generating massive profits. At the other end of the spectrum, small biotechs, most of which are still in their developmental stage, have been a hit-or-miss proposition, with a lot more hits and misses. Yet one group of small biotechs has been on fire, and gains look set to continue. Investors are only now coming to realize that the young, recently-public companies working on gene therapy aren't a flash in the pan, but a vanguard in the fight against many maladies. Since I profiled these stocks a year ago, they have exploded higher. On average, they have risen 191% over the past 12 months. (For more background, please read the April 2014 article.) View photo . The catalysts for these stocks are quite clear: either they have announced impressive clinical advances, or secured the endorsement (and financial backing) of the big drug makers. For example: In December 2014, bluebird bio, Inc. (Nasdaq: BLUE) announced that patients in early stage trial were given the company's LentiGlobin355 drug, and their need for chronic blood transfusions simply ceased. Shares surged when the news was announced, and they keep rising. [More from StreetAuthority.com: ] UniQure NV (Nasdaq: QURE) had been making a series of promising announcements regarding its drug development path throughout 2014. Yet shares really caught investors' attention earlier this month when Bristol-Myers Squibb Co. (NYSE: BMY) announced a deal to license UniQure's gene therapy platform, replete with a series of upfront and milestone payments. Shares of Celladon Corp. (Nasdaq: CLDN) had also been up more than 100% (since April 2014), but have recently sold off on concerns that the company's Mydicar drug may not have sufficient efficacy to merit FDA approval. Applied Genetic Technologies Corp. (Nasdaq: AGTC) has yet to garner much buzz with its drug development efforts. But what about Bluebird Bio and Uniqure? After delivering such great returns, do they still possess further robust upside? Yes, they do, for risk-tolerant investors with multi-year time horizons. Regarding UniQure, I noted a year ago that the company "appears to offer the most appealing broad-based approach to gene therapy, and its sub-$150 million market value also makes it a relative bargain." Well, that market value is now approaching $500 million, so we need to stop thinking of this stock as a bargain. Instead, it needs to be viewed in terms of its total addressable market opportunity. Simply put, the company's total addressable market opportunity is very large. In the second half of this year, UniQure will deliver a clinical trial update regarding patients that have Hemophilia B. Although it afflicts only one in every 25,000 people, current treatments are extremely costly. Patients require a $2,500 injection three times a week. Analysts at Leerink Swan, an investment firm solely-focused on healthcare, think that the Phase I/II data will prove to be the next catalyst for this stock, and they see nearly 100% upside to their $50 target price. [More from StreetAuthority.com: ] Investors shouldn't just focus on the Hemophilia progress. UniQure is working a wide range of gene therapy treatments. The company and Bristol-Myers Squibb have identified 10 in particular that are worthy of collaboration. And as UniQure announces clinical trial progress with each indication, BMY will issue milestone payments. That likely eliminates the need for dilutive secondary offerings, a key consideration with any young biotech firm. Analysts at BMO Capital are also bullish. They just initiated coverage of UniQure with a $49 price target, noting that the company's work in the area of congestive heart failure could prove to eventually develop very robust revenue streams. Here's where the important biotech caveat comes in: UniQure and other gene therapy firms are showing great progress early in their clinical development work, but investors won't fully believe in this medical approach until large-scale Phase III trials are well underway. That means such stocks require a multi-year time horizon. Bluebird bio faces similar opportunities and threats. The company's gene therapy technologies appear to hold great promise for sickle cell disease, ALD (the "Lorenzo's Oil" drug discussed in last year's article) and several other "monogenic" (or single gene disease) disorders. The key distinction between these gene therapy firms and other biotechs is that the gene therapy approach would yield a one-time permanent cure, rather than years of costly treatments, The actual number of sufferers of such disorders that the gene therapy firms are targeting is relatively small. Yet "single-treatment, gene therapy-based cures could be priced at $500,000-plus per patient in the developed markets, and still offer a compelling cost-benefit profile for payors and patients," note analysts at Roth Capital Partners.
al die mooie aanbevelingen, hoge koersdoelen etc....het kan toch geen toeval zijn? Beleggers worden massaal op het verkeerde been gezet. Gisteren bleef het aandeel stevig staan op een turbulente dag in de biotech met bijna 800k...en nu met geen nieuws en iets meer dan 50k in elkaar gerost (6% lager!)
twitter.com/dougheuringaria Roth $QURE Targeting CNS-disorders With AAVs
ROTH $QURE Compelling Opportunities Ahead t.co/fIgACJOkVM
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
CVC Capital Partners
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Indices
AEX
887,44
+0,99%
EUR/USD
1,0762
0,00%
FTSE 100
8.213,49
+0,51%
Germany40^
18.017,10
+0,67%
Gold spot
2.301,75
0,00%
NY-Nasdaq Composite
16.156,33
+1,99%
Stijgers
Dalers